HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

QLT0074

photosensitizer; structure in first source

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Dickey, Dwayne: 1 article (12/2007)
2.	Halls, Steve: 1 article (12/2007)
3.	Moore, Ronald B: 1 article (12/2007)
4.	Tulip, John: 1 article (12/2007)
5.	Xiao, Zhengwen: 1 article (12/2007)
6.	Bounds, D J: 1 article (06/2003)
7.	Granville, D: 1 article (06/2003)
8.	Hunt, D W C: 1 article (06/2003)
9.	Ip, S H: 1 article (06/2003)
10.	Jiang, H: 1 article (06/2003)

Related Diseases

1.	Photosensitivity Disorders (Photodermatitis) 06/01/2003 - "In the current study, the intracellular distribution of QLT0074 and the mode of cell death induced by photosensitization with this compound in vitro were assessed for transformed human HaCaT keratinocytes. " 06/01/2003 - "Appearance of the mitochondrial protein cytochrome c in the cytosolic fraction and expression of the apoptosis-associated mitochondrial 7A6 antigen were demonstrable following photosensitization at nano-molar levels of QLT0074. "
2.	Body Weight (Weight, Body) 04/01/2002 - "The study involved 60 mice receiving the same drug dose of a novel verteporfin-like photosensitizer, QLT0074, at 0.3 mg/kg body weight, followed by different light doses of 5, 10, 20, 30, 40 or 50 J/cm2 at 686 nm and a fluence rate of 70 mW/cm2. "
3.	Neoplasms (Cancer) 12/15/2007 - "Three hours after QLT0074 injection, tumors were illuminated by 690-nm light delivered by a computer-controlled switch, which sequentially directed light to one of the seven optical fibers in cycles. " 12/15/2007 - "Rats bearing anaplastic tumor treated by fractionated light (PDT dose: 1.5 mg/kg QLT0074, 900 J light) had a median survival of 51 days with 25% tumor cures compared with that of 26 days with no tumor cure by continuous illumination (P = 0.015) and 14 days by light-only (P = 0.0001). "
4.	Lymphoma (Lymphomas) 08/01/2002 - "The activity of QLT0074 was tested against human peripheral blood T cells and Jurkat T lymphoma cells. "

Related Drugs and Biologics

1.	Photosensitizing Agents (Photosensitizers)
2.	Verteporfin (Visudyne)
3.	Cytochromes c (Cytochrome c)
4.	Mitochondrial Proteins (Mitochondrial Protein)
5.	antigen 7A6
6.	1-phenyl-3,3-dimethyltriazene (PDT)

Related Therapies and Procedures

1.	Optical Fibers